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Fatty acids profile of consumed fat determines
both the composition and the functions of body lipids
(1, 2). Moreover, the quality and the quantity of
dietary fat is considered as one of the major factors
influencing the risk of cancer. Conjugated linoleic
acids (CLA), which are the positional and geometric
isomers of linoleic acid (cis-9, cis-12 C18:2, n-6,
LA) with two cis/trans unsaturated bonds separated
by one single bond, are naturally present in milk and
dairy products as well as in fat from ruminants. They
are investigated since 1970í as a group of polyunsat-
urated fatty acids with numerous health-promoting
properties (3, 4). CLA isomers can modify the risk of
many diet-relating disorders, such as: obesity, athero-
sclerosis, cardiovascular disease, diabetes, osteo-
porosis and different types of cancer (5), but their
action depends on the conformation of the isomer.
Moreover, precise mechanisms of their action are
still under investigation (6). Among many suggested
ways of action, interactions with essential fatty acids
in their metabolic pathways and anti- or prooxidant
properties are very interesting.
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Abstract: The aim of this study was to investigate how supplementation of diet of female Sprague-Dawley rats
with different doses of conjugated linoleic acids and for a varied period of time influences breast cancer risk,
fatty acids profile and lipids peroxidation in chemically induced mammary tumors. Animals were divided into
nine groups with different modifications of diet (vegetable oil, 1.0 or 2.0% of CLA) and period of supplemen-
tation, which lasted after (A), before (B) and before and after (BA) carcinogenic agent - 7,12-
dimethylbenz[a]anthracene administration at 50th day of life. Mammary adenocarcinomas occurred in all
groups, but CLA supplementation decreased the cancer morbidity. Two percent CLA seem to be excessive
because of the coexisting cachexia. Two CLA isomers (cis-9, trans-11 and trans-10, cis-12) were detected in
tumors but content of rumenic acid was higher. Dietary supplementation significantly influenced some unsatu-
rated fatty acids content (C18:2 n-6 trans, C20:1, C20:5 n-3, C22:2), but the anti- or prooxidant properties of
CLA were not confirmed. CLA can inhibit chemically induced mammary tumors development in female rats,
but their cytotoxic action seems not to be connected with lipids peroxidation. CLA isomers differ with their
incorporation into cancerous tissues and they influence the content of some other fatty acids.
Keywords: CLA, DMBA, mammary tumors, rats
Abbreviations: AOil = group of rats supplemented with vegetable oil after DMBA administration, A1% =
group of rats supplemented with 1.0% of CLA after DMBA administration, A2% = group of rats supplement-
ed with 2.0% of CLA after DMBA administration, BOil = group of rats supplemented with vegetable oil before
DMBA administration, B1% = group of rats supplemented with 1.0% of CLA before DMBA administration,
B2% = group of rats supplemented with 2.0% of CLA before DMBA administration, BAOil = group of rats
supplemented with vegetable oil before and after DMBA administration, BA1% = group of rats supplemented
with 1.0% of CLA before and after DMBA administration, BA2% = group of rats supplemented with 2.0% of
CLA before and after DMBA administration, CLA = conjugated linoleic acids, DMBA = 7,12-dimethyl-
benz[a]anthracene, FA = fatty acids, FAME = fatty acids methyl esters, GC = gas chromatography, MDA =
malonyldialdehyde, TBARS = thiobarbituric acid reactive substances, TEB = terminal end buds
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Many researchers emphasize that oxidative
stress is connected with the etiology of many above-
mentioned diseases. Lipids peroxidation, especially
polyunsaturated fatty acids peroxidation, as a result
of oxidative stress generates many biologically
active compounds. They can increase the oxidative
damage in cells as they can live relatively long and
are highly reactive. Aldehydes, which are one of the
groups of metabolites, interact with intracellular
compounds, especially with proteins and nucleic
acids, and can break the cell functions (7, 8).
Estimation of the fatty acids metabolites generated
during the lipids peroxidation facilitates the expla-
nation of the mechanism of arising of pathological
conditions, as well as the influence of fatty acids on
them. 
The aim of this study was to investigate how
supplementation of diet of female Sprague-Dawley
rats with different doses of conjugated linoleic acids
and for a varied period of time influences the breast
cancer risk. To find out the mechanism of CLA
action we also assessed the fatty acids profile and
concentration of lipids peroxidation products (thio-
barbituric acid reactive substances ñ TBARS) in
chemically induced mammary tumors. 
MATERIALS AND METHODS
Animals
The guiding principles in the use and care of
laboratory animals as well as the whole experiment
were approved by The Local Ethical Committee on
Animal Experiments. Female Sprague-Dawley rats
(n = 104, age ñ 30 days) were purchased from
Division of Experimental Animals, Department of
General and Experimental Pathology (Medical
University of Warsaw, Warszawa, Poland). They
were kept in animal room at 21OC, in a 12 h light :
12 h dark cycle and during the whole research they
were fed ad libitum a standard laboratory diet
Labofeed H (Fodder plant ìMorawskiî, Øurawia 19,
Kcynia, Poland) and water. Applied laboratory diet
is composed of 22.0% protein, 4.0% fat, 30.0%
starch, 5.0% fibre, 6.5% minerals. After the arrival
and 1-week adaptation period, the animals were ran-
domly divided into 9 groups with different dietary
supplementation. The total characteristics of experi-
mental groups is shown in Table 1. Moreover, at
50th day of life, all animals received intragastrically
via gavage a single dose of carcinogenic agent -
DMBA (7,12-dimethylbenz[a]anthracene, approx.
95%, Sigma-Aldrich) in the amount of 80 mg/kg
body weight. Diet of three groups was supplement-
ed with conjugated linoleic acid (Bio-C.L.A.,
Pharma Nord, Denmark), given via gavage in the
amount of 0.15 mL/day (1% in diet) and diet of three
other groups was supplemented with conjugated
linoleic acid (Bio-C.L.A., Pharma Nord, Denmark),
given via gavage in the amount of 0.30 mL/day (2%
in diet). Bio-C.L.A. contained two main CLA iso-
mers: cis-9, trans-11 (31.4 ± 0.0%) and trans-10, cis-
12 (33.3 ± 0.1%) as main fatty acids, and also oleic
acid (11.0 ± 0.0%), linoleic acid (10.2 ± 0.0%),
palmitic acid (4.6 ± 0.0%) and stearic acid (2.2 ±
0.0%). Three control groups received intragastrical-
ly vegetable oil in the amount of 0.15 mL/day.
Applied oil does not contain conjugated linoleic
acids and was purchased from Pharma Nord,
Denmark, where it is used as the substrate to Bio-
C.L.A. synthesis. This allowed us to minimize the
differences in fatty acids profile of applied diets.
Table 2 shows the fatty acid composition of applied
diets. Supplementation of diet was conducted after
(AOil, A1%, A2%), before (BOil, B1%, B2%) and
before and after (BAOil, BA1%, BA2%) DMBA
administration. During the experiment, rats were
weighed weekly and palpated to detect the appear-
ance of tumors. The entire experiment lasted for the
following 21 weeks. In the 21st week of the experi-
ment, most of the animals were decapitated and
exsanguinated, and the weight of internal organs
were determined. Only animals of A2% and BA2%
groups were decapitated in the 15th week of the
experiment, because of their much lower body
weight and cachexia. 
Histopathological examination
DMBA treatment caused the mammary tumors
induction, which effectiveness was determined as
the percentage of animals with tumors in each
group. Some of the tumors collected during necrop-
sy (usually three in each group), selected randomly,
were fixed in 10% formalin and were identified as
adenocarcinomas and papillary adenocarcinomas of
mammary gland. 
Preparation of experimental material
Mammary tumors were collected during
necropsy and stored at -20OC until being analyzed.
Fatty acids analysis
Fatty acid analysis was made by means of gas
chromatography (GC) with capillary column and
flame-ionization detection. Mammary tumors were
thawed only once and three parallel samples of 0.2 g
were taken for lipids extraction according to Folch
et al. with minor modification (9). Purified organic
extract was evaporated to dryness under a stream of
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nitrogen and weighed to estimate the content of
lipids in tumor tissue. The fat content was calculat-
ed as the percentage share of fat weight in tumor tis-
sue [%]. The residue was taken for the preparation
of fatty acids methyl esters (FAME) according to
procedure of Bondia-Pons et al. with minor modifi-
cations (10), previously described for serum (11).
Briefly, FAME were separated and quantified using
Shimadzu GC-17A gas chromatograph with flame
ionization detector. Injector was heated to 250OC
and detector was heated to 270OC. Separation of
FAME was performed on BPX70 capillary column
(60 m ◊ 0.25 mm i.d., film thickness: 0.20 µm, SGE)
with helium as the carrier gas. The initial oven tem-
perature was 140OC for 1 min, thereafter increased
by 20OC/min to 200OC and hold for 20 min and then
increased by 5OC/min to 220OC and hold for 25 min.
Standards of CLA methyl esters: cis-9, trans-11
CLA and trans-10, cis-12 CLA were purchased from
Nu-Chek-Prep. Inc., USA. Peaks of CLA isomers in
examined samples were identified by comparison
with retention time of standards and quantified by
regression formula obtained with the standards.
CLA content was expressed in relation to fat content
and to tumor tissue weight.
TBARS analysis
From tumors thawed for fatty acids analysis,
sample of 0.5 g was taken for TBARS analysis with
spectrophotometric method (12). This sample was
Table 2. Fatty acids composition of applied diets.
Fatty acid [%] Fodder + oil Fodder + 1.0% CLA Fodder + 2.0% CLA
C6:0 0.11 ± 0.01 0.12 ± 0.00 ñ
C8:0 ñ 0.02 ± 0.00 0.05 ± 0.03
C10:0 0.01 ± 0.00 0.03 ± 0.00 0.04 ± 0.00
C11:0 0.01 ± 0.00 ñ 2.42 ± 0.01
C12:0 0.02 ± 0.00 0.06 ± 0.08 0.02 ± 0.00
C14:0 0.12 ± 0.01 0.12 ± 0.01 0.09 ± 0.05
C15:0 0.07 ± 0.01 ñ 0.07 ± 0.00
C16:0 10.49 ± 0.13 11.16 ± 0.23 10.12 ± 0.02
C16:1 0.13 ± 0.00 0.13 ± 0.00 0.13 ± 0.00
C17:0 0.08 ± 0.00 0.08 ± 0.00 0.07 ± 0.00
C18:0 2.53 ± 0.01 2.47 ± 0.03 2.42 ± 0.00
C18:1 n-9 34.46 ± 0.10 15.87 ± 0.16 15.59 ± 0.04
C18:2 n-6 cis 35.11 ± 0.05 31.46 ± 0.31 27.17 ± 0.07
cis-9, trans-11 CLA ñ 8.57 ± 0.34 12.41 ± 0.13
trans-10, cis-12 CLA ñ 8.47 ± 0.38 12.37 ± 0.10
C18:3 n-3 14.15 ± 0.01 16.69 ± 0.19 13.70 ± 0.02
C20:0 0.24 ± 0.12 ñ ñ
C20:1 0.36 ± 0.01 0.38 ± 0.00 0.49 ± 0.08
C20:3 n-6 0.04 ± 0.06 0.01 ± 0.00 ñ
C20:3 n-3 0.02 ± 0.00 0.04 ± 0.02 ñ
C20:5 n-3 0.06 ± 0.01 0.10 ± 0.02 0.08 ± 0.00
C21:0 0.06 ± 0.00 0.07 ± 0.00 0.06 ± 0.01
C22:0 0.20 ± 0.10 0.16 ± 0.01 0.13 ± 0.01
C22:1 n-9 0.04 ± 0.00 0.04 ± 0.00 0.03 ± 0.00
C22:2 0.12 ± 0.00 ñ ñ  
C23:0 ñ 0.12 ± 0.01 ñ
C24:0 0.15 ± 0.04 0.06 ± 0.05 0.09 ± 0.05
C24:1 0.10 ± 0.00 ñ ñ 
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mechanically homogenized with Teflon homogeniz-
er in 2.5 mL of sodium chloride solution (0.9%).
Afterwards, 2.5 mL of phosphate buffer (pH 7.0)
and 1.5 mL of trichloroacetic acid (1.7 mol/L), were
added to 0.5 mL of previously obtained
homogenate. The whole sample was shaken vigor-
ously and centrifuged for 15 min at 4000 rpm at 0OC,
to separate the protein sediment. One milliliter of 2-
thiobarbituric acid solution (69 mmol/L) was added
to 3.0 mL of supernatant; the whole sample was
shaken vigorously and heated for 15 min at boiling
water bath. Three parallel samples were prepared for
each tumor. The absorbance of samples was meas-
ured at λ = 530 nm after their cooling to room tem-
perature. The reference sample was prepared analo-
gously with 0.5 mL of sodium chloride solution
(0.9%). TBARS content was quantified in relation to
fat content and to tumor tissue weight.
Statistical analysis 
All data are shown as the mean values ± standard
deviation. For variables with skew distribution, data
were transformed in logarithms and retransformed
after calculations. Obtained results were evaluated
with Statistica 9.0 (StatSoft, Poland) and GraphPad
prism v.3.02 (GraphPad Software, USA). Due to the
lack of normal distribution for some variables and to
the relatively small number of examined tumors in
some groups, the data were tested with Kruskal-Wallis
test and verified with Dunnís multiple comparison
test; p-value < 0.05 was considered significant. 
RESULTS
DMBA given intragastrically in a single dose
of 80 mg/kg body weight was effective in the induc-
tion of mammary tumors. They appeared during the
experiment in all groups and were identified as ade-
nocarcinomas and papillary adenocarcinomas of
mammary gland. The percentage of tumor-bearing
animals in each group is shown in Table 1. 
The higher cancer morbidity was observed in
groups BOil and B2%. In those groups all animals
suffered from mammary tumors. Nevertheless, we
Figure 1. Changes of average body weight during the experiment of groups supplemented before DMBA administration
Figure 2. Changes of average body weight during the experiment of groups supplemented after DMBA administration
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observed diminished induction of cancerous process
in most of CLA supplemented groups. The preven-
tive effect was the strongest in BA2% group, where
breast cancer appeared only in one of nine animals.
Also in A2% group the cancer morbidity was much
smaller than in other groups. Furthermore, animals
supplemented with the lower dose of CLA (1.0%)
were less prone to chemically induced carcinogene-
sis than animals from similar groups receiving veg-
etable oil. The mammary tumors appeared and were
palpated in 20-21 week of life, much later than in
groups supplemented with oil. Taking into account
other parameters characterizing the cancer morbidi-
ty, such as total weight of tumors and total number of
tumors, we observed significant differences among
all examined groups (p = 0.0080 and p < 0.0010,
respectively). The preventive properties of CLA
were also reflected by the diminished number and
smaller size of tumors in A2% and BA2% groups. 
During the whole experiment, the mean body
weight of each group was checked weekly. There
were no significant differences in body weight
among those groups, which were fed the modified
diets before the DMBA administration (Fig. 1). We
observed the significant influence of diet supple-
mentation with higher dose of CLA on body weight
in A2% and BA2% groups (Figs. 2 and 3). From 7th
week of the experiment, their mean body weight
were much lower than body weight of other ani-
mals, which indicates that they did not utilize the
forage as effectively as other groups. Moreover, the
action of CLA was bound with the toxic effect of
carcinogenic agent treatment and caused the
exhaustion of the animals. The continuation of the
experiment for A2% and BA2% group was impos-
sible because of the cachexia of animals and for
those groups the experiment was terminated at 15th
week (Figs. 2 and 3). 
Figure 3. Changes of average body weight during the experiment of groups supplemented before and after DMBA administration
Figure 4. Mean body weight gained by each experimental group at 15th week of experiment. The same superscripts mean, that the val-
ues differ with p < 0.05
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We compared the mean weight gained at 15th
week of experiment in each group (Fig. 4). There
were significant differences among examined
groups (p < 0.0001). The lowest weight gained two
groups supplemented with the higher dose of CLA
for a long period of time. Such body weight lower-
ing effect was not observed with the supplementa-
tion with 1.0% dose of CLA. On the contrary, A1%
group gained the highest weight of all examined
groups at 15th week of experiment.
The earlier termination of the experiment for
A2% and BA2% group also significantly influences
the weight of internal organs, as their weights were
the lowest in these two groups (Table 3). However,
the applied modification of diet also had a signifi-
cant impact on the organsí weight. The highest mean
weight of liver was determined for BOil group,
whereas A1% group gained the highest weight of
kidneys and heart. As far as weight of spleen is con-
sidered, we observed great differences among indi-
viduals in all investigated groups but also significant
differences among groups. The efficiency of DMBA
action also modified the organsí weight, as the com-
parison of these parameters revealed their signifi-
cantly higher values for individuals suffering from
mammary tumors than in individuals without breast
cancers (data not shown).
Fatty acids methyl esters (FAME) profiles in
fat isolated from mammary tumors were determined
using GC. In our experiment, we were able to iden-
tified 32 fatty acids in tumors. The following fatty
acids were found to be the main fatty acids in the
tumors of all investigated groups: palmitic C16:0,
oleic C18:1 n-9 cis, linoleic C18:2 n-6 cis, arachi-
donic C20:4 n-6 and stearic C18:0 (Table 4). 
There were significant differences in the con-
centration of some of the fatty acids among exam-
ined groups (Tables 4 and 5).
Two main saturated fatty acids were detected
in the highest amounts in tumors from B2% group
(C16:0) and BOil (C18:0), whereas their content in
samples from BAOil (C16:0) and B1% (C18:0) was
the lowest. In BAOil group we also detected the
highest share of main monounsaturated acid - oleic
acid, while the lowest concentration of this acid was
characteristic for B2% group. Among polyunsatu-
rated fatty acids, concentration of linoleic acid was
the highest in fat fraction of mammary tumors but its
content differed significantly among individuals in
each group. We observed its highest content in
tumors obtained from BAOil group. Moreover, can-
cerous tissues from this group were also character-
ized by the lowest content of arachidonic acid ñ the
main metabolite of linoleic acid. Similar depend-
ence was observed also for α-linoleic acid (C18:3 n-
3), which content in BAOil was the highest among
all investigated groups, and its metabolite - eicosa-
pentaenoic acid (C20:5 n-3), which content in this
group was the smallest. As far as docosahexaenoic
acid (C22:6, n-3), the other ALA metabolite is con-
cerned, its lowest amount was detected in adenocar-
cinomas from A2% and the highest ñ in BOil
groups. The highest concentration of arachidonic
acid was detected in a single analyzed tumor from
BA2%. 
Two main CLA isomers identified as cis-9,
trans-11 CLA and trans-10, cis-12 CLA, were
detected in mammary tumors from all investigated
groups. Bio-C.L.A. used as the source of CLA con-
sisted of several fatty acids, with prevailing share of
two CLA isomers: trans-10, cis-12 CLA (33%) and
cis-9, trans-11 CLA, rumenic acid (31%) (13). We
observed that the applied dose of CLA supplement
influenced their content in adenocarcinomas of
mammary glands as the highest content of both CLA
isomers were detected in groups supplemented with
the higher dose of CLA and their content in groups
supplemented with vegetable oil was minimal. Cis-
9, trans-11 CLA was shown to be the predominant
CLA isomer in fat from mammary tumors of all
groups, while trans-10, cis-12 CLA was detected in
lower amounts, although their concentration in
applied diets was similar (Table 2). The highest con-
tent of rumenic acid was detected in A2% group
(1.16 ± 0.98%) while trans-10, cis-12 constituted
only 0.74 ± 0.73% of FA in mammary tumors from
this group. 
There were no significant differences in tumors
fat content among examined groups, although some
tendencies were observed ñ its content was elevated
in mammary tumors obtained from groups supple-
mented with higher dose of CLA (Table 3). It was
not possible to quantify the absolute content of CLA
isomers in each group, as their amounts were below
the limit of quantification. Only their percentage
share in the total pool of fatty acids was evaluated.
Especially in groups receiving vegetable oil or sup-
plemented with CLA for a very short period of time,
content of CLA isomers was below the quantifica-
tion limit in some individuals. Moreover, in all
investigated groups there were significant differ-
ences in both isomers content among individuals
(Table 3). The highest concentration of rumenic acid
(in fat fraction and in tissue) was determined in
A2% group, whereas in BOil it was not possible to
quantify its content. Adenocarcinomas of A2% were
also characterized by the highest mean content of
trans-10, cis-12 CLA. Furthermore, mean content of
1170 AGNIESZKA BIA£EK et al.
T
ab
le
 3
. C
om
pa
ri
so
n 
of
 m
ea
n 
w
ei
gh
ts
 o
f 
or
ga
ns
 a
nd
 f
at
, C
L
A
 a
nd
 T
B
A
R
S 
co
nt
en
t i
n 
m
am
m
ar
y 
tu
m
or
s.
G
ro
up
s 
of
 a
ni
m
al
s 
A
O
il
A
1%
A
2%
B
O
il
B
1%
B
2%
B
A
O
il
B
A
1%
B
A
2%
p 
va
lu
e 
L
iv
er
 [
g]
6.
48
 ±
 0
.5
7a
6.
20
 ±
 0
.9
1
5.
58
 ±
 0
.4
7
6.
73
 ±
 1
.6
2
5.
63
 ±
 0
.4
1
5.
75
 ±
 0
.6
1
6.
56
 ±
 1
.3
4
6.
13
 ±
 0
.6
9
5.
35
 ±
 0
.6
3a
0.
00
13
K
id
ne
ys
 [
g]
1.
81
 ±
 0
.0
7a
,b
1.
83
 ±
 0
.1
8c
,d
1.
41
 ±
 0
.0
8a
,c
,e
,f
,g
,h
1.
71
 ±
 0
.1
8e
1.
62
 ±
 0
.1
3
1.
74
 ±
 0
.1
7f
1.
70
 ±
 0
.1
4g
1.
63
 ±
 0
.3
1h
1.
50
 ±
 0
.1
6b
,d
< 
0.
00
01
Sp
le
en
 [
g]
0.
81
 ±
 0
.2
5a
,b
0.
71
 ±
 0
.2
3c
0.
42
 ±
 0
.0
4a
,c
,d
,e
,f
,g
,h
0.
71
 ±
 0
.2
8d
,e
0.
61
 ±
 0
.3
0
0.
67
 ±
 0
.1
4f
0.
76
 ±
 0
.3
0g
0.
71
 ±
 0
.2
3h
0.
49
 ±
 0
.0
9b
< 
0.
00
01
H
ea
rt
 [
g]
0.
84
 ±
 0
.0
4
0.
95
 ±
 0
.1
5a
0.
72
 ±
 0
.0
4a
,b
,c
,d
,e
0.
92
 ±
 0
.0
9b
0.
88
 ±
 0
.0
9c
0.
79
 ±
 0
.0
5f
,g
0.
93
 ±
 0
.1
0d
,f
,h
0.
92
 ±
 0
.1
2e
,g
0.
79
 ±
 0
.0
8h
< 
0.
00
01
Fa
t [
%
]
2.
27
 ±
 0
.8
4
2.
13
 ±
 1
.2
5
2.
60
 ±
 0
.7
6
2.
32
 ±
 1
.0
3
2.
30
 ±
 1
.3
0
1.
68
 (
0.
69
 ñ
 4
.1
4)
*
2.
17
 ±
 1
.3
5
2.
52
 ±
 1
.4
6
4.
58
0.
80
79
ci
s-
9,
 tr
an
s-
11
 C
L
A
 
56
.4
22
87
.4
 
36
90
.7
 (
13
55
.9
 ñ
96
.5
 ±
 0
.0
0
78
.8
 ±
 6
6.
2 
80
8.
6 
± 
74
9.
5 
26
9.
6
30
68
.9
 ±
  
29
03
.8
 
0.
00
20
[m
g/
g 
of
 f
at
] 
(1
4.
0 
ñ 
22
7.
6)
* 
± 
10
30
.1
10
04
5.
3)
* 
 
(9
0.
6 
ñ 
80
2.
0)
*,
a
25
07
.9
a
ci
s-
9,
 tr
an
s-
11
 C
L
A
1.
8 
± 
1.
4a
,b
65
.9
 ±
 4
3.
4 
11
2.
2
0.
6 
(0
.0
 ñ
 
2.
6 
± 
2.
3 
22
.6
 ±
 2
1.
5 
5.
8 
± 
2.
4c
63
.8
(1
6.
8 
ñ
[m
g/
g 
of
 ti
ss
ue
] 
(2
2.
9 
ñ 
55
0.
7)
*,
a
13
.4
)*
 
24
2.
4)
*,
b,
c
72
.1
 
0.
00
03
tr
an
s-
10
, c
is
-1
2 
C
L
A
 
14
28
.8
 ±
 
40
87
.7
 ±
 
31
.9
 ±
 0
.0
 
63
2.
4 
(1
56
.7
 ñ
 
26
5.
7 
(4
0.
5 
ñ 
16
54
.5
 ±
 
14
62
.1
 0
.3
01
8
[m
g/
g 
of
 f
at
]
88
5.
3 
33
63
.8
25
52
.3
)*
17
42
.2
)*
14
57
.9
tr
an
s-
10
, c
is
-1
2 
C
L
A
46
.0
 ±
 4
0.
1 
85
.1
15
.8
 ±
 3
.7
 
5.
8 
± 
3.
3 
28
.1
35
.4
 
0.
13
20
[m
g/
g 
of
 ti
ss
ue
]
(1
4.
0 
ñ 
51
6.
2)
* 
2.
7 
± 
0.
0 
(4
.5
 ñ
 1
73
.5
)*
T
B
A
R
S 
24
.3
 ±
 1
7.
6 
20
.6
 ±
 5
.7
 
24
.0
 ±
 1
5.
0 
32
.1
 ±
 1
6.
3 
23
.7
 ±
 1
6.
4 
17
.8
 ±
 1
7.
0 
30
.3
 ±
 1
7.
9 
36
.2
 ±
 1
8.
5 
35
0.
1 
0.
50
42
[n
m
ol
/g
 o
f 
tis
su
e]
 
T
B
A
R
S 
1.
18
 ±
 1
.1
1 
1.
17
 ±
 0
.7
3 
0.
87
 ±
 0
.3
0 
1.
58
 ±
 1
.2
7 
1.
03
 ±
 0
.8
 
1.
20
 ±
 1
.1
4 
1.
35
1.
67
 ±
 0
.9
2 
7.
64
 
0.
82
84
[m
m
ol
/g
 o
f 
fa
t]
(0
.2
9 
ñ 
6.
19
)*
 
A
O
il 
ñ 
gr
ou
p 
of
 r
at
s 
su
pp
le
m
en
te
d 
w
ith
 v
eg
et
ab
le
 o
il 
af
te
r 
D
M
B
A
 a
dm
in
is
tr
at
io
n,
 A
1%
 ñ
 g
ro
up
 o
f 
ra
ts
 s
up
pl
em
en
te
d 
w
ith
 1
.0
%
 o
f 
C
L
A
 a
ft
er
 D
M
B
A
 a
dm
in
is
tr
at
io
n,
 A
2%
 ñ
 g
ro
up
 o
f 
ra
ts
 s
up
pl
em
en
te
d 
w
ith
 2
.0
%
of
 C
L
A
 a
ft
er
 D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
O
il 
ñ 
gr
ou
p 
of
 r
at
s 
su
pp
le
m
en
te
d 
w
ith
 v
eg
et
ab
le
 o
il 
be
fo
re
 D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
1%
 ñ
 g
ro
up
 o
f 
ra
ts
 s
up
pl
em
en
te
d 
w
ith
 1
.0
%
 o
f 
C
L
A
 b
ef
or
e 
D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
2%
ñ 
gr
ou
p 
of
 r
at
s 
su
pp
le
m
en
te
d 
w
ith
 2
.0
%
 o
f 
C
L
A
 b
ef
or
e 
D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
A
O
il 
ñ 
gr
ou
p 
of
 r
at
s 
su
pp
le
m
en
te
d 
w
ith
 v
eg
et
ab
le
 o
il 
be
fo
re
 a
nd
 a
ft
er
 D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
A
1%
 ñ
 g
ro
up
 o
f 
ra
ts
 s
up
pl
em
en
te
d
w
ith
 1
.0
%
 o
f 
C
L
A
 b
ef
or
e 
an
d 
af
te
r 
D
M
B
A
 a
dm
in
is
tr
at
io
n,
 B
A
2%
 ñ
 g
ro
up
 o
f 
ra
ts
 s
up
pl
em
en
te
d 
w
ith
 2
.0
%
 o
f 
C
L
A
 b
ef
or
e 
an
d 
af
te
r 
D
M
B
A
 a
dm
in
is
tr
at
io
n.
 A
ll 
da
ta
 a
re
 s
ho
w
n 
as
 th
e 
m
ea
n 
va
lu
es
 ±
 s
ta
nd
ar
d 
de
vi
-
at
io
n.
 F
or
 v
ar
ia
bl
es
 w
ith
 s
ke
w
ed
 d
is
tr
ib
ut
io
n 
(*
),
 d
at
a 
w
er
e 
tr
an
sf
or
m
ed
 in
 lo
ga
ri
th
m
s 
an
d 
re
tr
an
sf
or
m
ed
 a
ft
er
 c
al
cu
la
tio
ns
; d
at
a 
ar
e 
sh
ow
n 
as
 m
ea
n 
an
d 
co
nf
id
en
ce
 in
te
rv
al
. p
 v
al
ue
 <
 0
.0
5 
- 
si
gn
if
ic
an
t d
if
fe
re
nc
es
am
on
g 
gr
ou
ps
 in
 K
ru
sk
al
ñW
al
lis
 te
st
; v
al
ue
s 
w
ith
 th
e 
sa
m
e 
su
pe
rs
cr
ip
ts
 d
if
fe
r 
si
gn
if
ic
an
tly
. 
Conjugated linoleic acids (CLA) decrease the breast cancer risk in... 1171
this isomer in fat fraction of A2% tumors was high-
er than the content of cis-9, trans-11 CLA, although
in other investigated groups the tendency was oppo-
site ñ we detected higher amounts of rumenic acid
than trans-10, cis-12 CLA. The highest concentra-
tions of CLA isomers were revealed in mammary
tumors obtained from groups supplemented with
2.0% of Bio-C.L.A., which indicates the influence
of applied dose on the CLA isomers content in can-
cerous tissues.
TBARS content in mammary tumors was
determined with spectrophotometric method and
was express also in terms of fat content as it is con-
sidered as an indicator of lipids peroxidation
processes. Results for TBARS are summarized in
Table 3. Although we detected very high concentra-
tion of TBARS in one mammary tumor of BA2%
group, we found this result as an outlier and this sin-
gle result was not included into statistical analysis.
The comparison of TBARS content in cancerous tis-
sues from other investigated groups did not reveal
any significant differences. Moreover, we observed
large diversity in results among individuals in inves-
tigated groups. 
DISCUSSION AND CONCLUSION
Some species of laboratory animals treated with
carcinogenic agent become prone to cancer develop-
ment. In our experiment, single DMBA treatment of
Sprague-Dawley female rats at 50th day of life
caused the mammary tumors appearance in all
groups. They were identified as adenocarcinomas and
papillary adenocarcinomas of mammary gland. Our
previous experiment (14), as well as the experiments
conducted by other researchers (15-18) revealed the
usefulness of this model in breast cancer research. We
observed the significant anticarcinogenic properties
of CLA: diminished breast cancer morbidity and
decreased weight and number of mammary tumors in
CLA supplemented groups (Table 1). This observa-
tion is in accordance with our previous results (11,
19) and with the results of others. Corl et al. detected
that CLA as well as its precursor - vaccenic acid
administration decreased the mammary tumors risk in
laboratory animals (20, 21). Also Ip et al. observed
that 0.5%, 1.0% and 1.5% of CLA reduced the num-
ber of malign and benign breast tumors in female rats
(17). Moreover, even smaller doses of CLA
(0.05ñ0.5%) given to rats for 9 months effectively
prevented the breast cancer development. They
observed also that short (5 weeks) administration of
CLA before DMBA treatment at 50th day of life
diminished this cancer risk (17). Thompson et al.,
who compared 1-month supplementation with 1.0%
CLA before DMBA treatment and 6-month supple-
mentation, revealed the high effectiveness of short
CLA administration followed by the carcinogenic
agent administration (18). Our results ñ the lower
cancer morbidity in B1% group, receiving 1.0% of
CLA mixture only for 14 days (from 37th till 50th day
of life) ñ confirm protective efficacy of CLA admin-
istered in early stage of life, before cancerous process
induction. Ip et al. explained that CLA given early,
when mammary glands maturate, cause a decrease in
TEB cellsí number and stimulate their differentiation
(17). This brought about the decrease of the amount
of potential places of cancerous process initiation,
because TEB are the main places of adenocarcinomas
induction in mammary glands of rodents (22).
However, addition of CLA to diet after carcinogenic
agent treatment also diminished the number of
breast tumors and their growth (23). The activity of
CLA depends on their dose in diet and its maximum
is observed at 1.0%, regardless the carcinogenic
agent and other dietary lipids presence (24). We
observed the higher anticancer effectiveness of
2.0% CLA but this dose seems to be too high
because of the cachexia stimulation. Our results
ostensibly disagree with the statement of Pariza et
al., who claimed that one of the CLA influence on
cancerous process is through the cachexia inhibition
(25). However, this effect is attributed to rumenic
acid, whereas trans-10, cis-12 CLA does not demon-
strate such activity. The fact, that applied prepara-
tion contained the mixture of two main CLA iso-
mers, may cause such incompatibilities. 
We observed much lower mean body weight of
animals supplemented with higher dose of CLA
since 7th week of experiments, what was the reason
of their earlier decapitation. Many researchers
emphasized the ability of CLA isomers to reduce the
body mass. Especially trans-10, cis-12 CLA seems
to be potent and its action has few potential mecha-
nisms: reduction of lipoprotein lipase activity,
diminished differentiation of preadipocytes into
adipocytes through the genes inhibition and stimula-
tion of lipids β-oxidation by activation of crucial
enzymes expression (26, 27). Bio-C.L.A., which we
used as a source of conjugated linoleic acids, con-
sisted of few fatty acids with prevailing share of two
CLA isomers: cis-9, trans-11 and trans-10, cis-12,
which were present in equal amounts (Table 2).
High intake of trans-10, cis-12 CLA seemed to be
responsible for much lower weight gained by ani-
mals supplemented with 2.0% of CLA. Our results
are in accordance with those obtained by He et al.,
who applied synthetic isomers of CLA to laboratory
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animals, and observed much lower body weight in
comparison with control group (28). However, Ip et
al. did not detect any differences in total body
weight gained by rats treated with DMBA and sup-
plemented with different doses of CLA (0.5ñ1.0%)
(16). 
Applied modification of diet significantly
influenced the weight of internal organs. These
observations disagreed with those made by others
researchers. After 8-week supplementation with two
doses of cis-9, trans-11 CLA Turpeinen et al. did not
revealed any differences in heart, liver, spleen and
pancreas weight (29). Also in much longer experi-
ment of Ip. et al., with usage of CLA mixture and
carcinogenic agent, there were no differences in
internal organs weight (16). However, when they
gave single trans-10, cis-12 CLA to mice treated
with chemical carcinogen, they observed signifi-
cantly higher weight of livers, hearts and spleen.
Moreover, after cis-9, trans-11 CLA application,
there were no such effects (30). This may suggest
that effects of two major CLA isomers are opposite.
Furthermore, our results show that coexisting can-
cerous process significantly influences both the total
body weight (especially by the mass of tumors) and
internal organs weight. 
As far as fatty acids profile in mammary
tumors is considered, we detected significant influ-
Table 5. Results of Dunnís multiple comparison test for fatty acids content in mammary tumors.
Compared Dunn test 
groups p value
C10:0
A2% vs. BA1% < 0.01   
B2% vs. BA1% < 0.001
C16:0
AOil vs. BAOil < 0.05
B2% vs. BAOil < 0.05
C18:1 n-9 cis B2% vs. BAOil < 0.05
C18:2 n-6 cis B2% vs. BAOil < 0.05
AOil vs. BOil < 0.05
C18:2 n-6 trans AOil vs. B1% < 0.05
AOil vs. B2% < 0.01
C20:1
AOil vs. A2% < 0.01
AOil vs. BA1% < 0.01
A2% vs. BA1% < 0.05
BOil vs. BA1% < 0.01
C22:2
B1% vs. BA1% < 0.05
B2% vs. BA1% < 0.01
AOil vs. BA1% < 0.05
A1% vs. BOil < 0.01
cis-9, trans-11
A2% vs. BOil < 0.01
CLA
BOil vs. BA 1% < 0.001
B2% vs. BA 1% < 0.01
AOil vs. BA1% < 0.05
A2% vs. B1% < 0.05
trans-10, cis-12
B1% vs. BA1% < 0.05
CLA
B2% vs. BA1% < 0.05
BAOil vs. BA1% < 0.05
AOil ñ group of rats supplemented with vegetable oil after DMBA administration, A1% ñ group of rats supplemented with 1.0% of CLA
after DMBA administration, A2% ñ group of rats supplemented with 2.0% of CLA after DMBA administration, BOil ñ group of rats sup-
plemented with vegetable oil before DMBA administration, B1% ñ group of rats supplemented with 1.0% of CLA before DMBA admin-
istration, B2% ñ group of rats supplemented with 2.0% of CLA before DMBA administration, BAOil ñ group of rats supplemented with
vegetable oil before and after DMBA administration, BA1% ñ group of rats supplemented with 1.0% of CLA before and after DMBA
administration, BA2% ñ group of rats supplemented with 2.0% of CLA before and after DMBA administration.
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ence of applied diet on the content of some of fatty
acids. Significant differences referred only to 9 of 32
analyzed fatty acids. Many authors compared the
fatty acids profile in adipose tissue of mammary
glands and other tissues of animals receiving CLA.
Banni et al. observed lack of influence of 1.0% CLA
on linoleic acid amount in adipose tissue of mam-
mary glands but their distinct influence on reduction
of linoleic acids metabolites: C18:3, C20:3 and
arachidonic acid (22). Eder et al. also detected that
CLA supplementation decreased the concentration
of arachidonic acid as well as all n-6 fatty acids in
hepatic phospholipids (31). Experiment of Cao et al.
showed that 1.0% CLA in maternal diet reduced the
arachidonic acid concentration in hepatic phospho-
lipids of progeny, whereas 2.0% CLA had the oppo-
site effect. Moreover, the impact of above men-
tioned diet modification on α-linolenic concentra-
tion was opposed while the linoleic acid amount was
raised in both groups (32). Influence of CLA on
other n-3 and n-6 fatty acids concentration was also
divers. CLA supplementation increased the content
of docosahexaenoic acid and all n-3 fatty acids in
hepatic phospholipids (31). However, information
concerning the impact of CLA supplementation on
fatty acids profile in cancerous tissues is limited.
One of the causes is the shortage of sufficient
amounts of experimental material. Because of very
low content of many fatty acids in cancerous tissues
compared with normal tissues, detection of some
fatty acids is difficult. Especially in relation to n-3
fatty acids these reasons are important. Senkal et al.
detected much lower content of docosahexaenoic
acid and eicosapentaenoic acid in gastrointestinal
tumors than in livers (33). Results obtained by
Hoffman et al. also confirmed lower levels of
docosahexaenoic acid in cancerous than in normal
tissues (34). For CLA isomers incorporation into
cancerous tissues, the tendency is opposite, as their
concentration in such tissues is much higher than in
normal ones (34). However, comparison of CLA
content in malign and benign mammary tumors
revealed the lack of significant differences among
them (35) or higher CLA content in benign tumors
(36). CLA are easier incorporated into triacylglyc-
erols than in phospholipids, that is why their content
in neutral lipids is higher than in phospholipids (37,
38). They are built into nucleus and cytosol and their
content in cellular membranes and mitochondria is
much lower. Their incorporation into cellular frac-
tions is similar with that of monounsaturated fatty
acids (34). We detected higher content of cis-9,
trans-11 CLA than of trans-10, cis-12 CLA in mam-
mary tumors. Tsuzuki et al. claim that these differ-
ences are the results of different metabolism of main
CLA isomers, while only trans-10, cis-12 activates
β-oxidation of fatty acids and facilitates its own
metabolism (39). 
Results of many studies emphasize the higher
content of TBARS in serum of patients suffering
from different types of cancer: breast, lungs, stom-
ach, small intestine (7, 8). Czeczot et al. detected
higher concentration of TBARS than in control tis-
sues in all investigated types of tumors, except
malign liver tumors. Obtained results indicate that
malignancy and proliferation of cells are connected
with low level of lipids peroxidation (40). Some
authors claimed that CLA possess strong antioxidant
properties. Ha et al. found CLA to be as potent
antioxidant as α-tocopherol and almost as strong as
butylhydroxytoluene (41). Ip et al. also confirmed
that CLA can inhibit the lipids peroxidation,
because the levels of malonyldialdehyde in tissues
were much lower after CLA treatment (24).
Furthermore, they observed the strongest anti-
cancerogenic effect of 1.0% CLA, whereas 0.25%
CLA was the most effective dose to inhibit the
TBARS formation in tissues. CLA mixture given to
animals caused the decrease of TBARS levels in
their mammary glands (16). However, Chen et al.
observed much higher concentration of TBARS in
plasma of mice with gastrointestinal tumors treated
with rumenic acid or trans-10, cis-12 CLA (42).
Turpeinen et al. also detected much higher concen-
tration of 8-isoPGF2α in urine of animals receiving
both CLA mixture and single trans-10, cis-12 CLA,
what suggests the pro-oxidative properties of CLA
(29). Moreover, Stachowska et al. indicated that
CLA increased formation of reactive oxygen species
(ROS) in macrophages (43). According to many
researchers, an increased peroxidation of lipids
caused by CLA supplementation is connected with
cytotoxic effect of conjugated fatty acids against
cancer cells. An increased susceptibility to oxidation
of n-3 polyunsaturated fatty acids is, according to
many authors, the main cause of their chemopreven-
tive properties. Products of their oxidation act toxic
at cancerous cells (44). Osinsky et al., who detected
higher concentration of malonyldialdehyde in
tumors after administration of cobalt complexes,
found this effect to be beneficial (45). We detected
much higher content of TBARS in mammary tumor
of BA2% group, but we did not observed any differ-
ences in concentration of TBARS among other
investigated groups. Our results do not confirm nei-
ther prooxidant nor antioxidant properties of CLA.
However, it seems to be advantageous to evaluate
the TBARS and other biofactors content in serum or
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other tissues. This will help to recognize the overall
oxidation status of the organism and will explain the
influence of CLA supplementation on lipids and
other compounds oxidation. 
Our results confirm that conjugated linoleic
acids can inhibit chemically induced mammary
tumors development in female rats, but their cyto-
toxic action seems not to be connected with lipids
peroxidation. Cis-9, trans-11 CLA and trans-10, cis-
12 CLA differ with their incorporation into cancer-
ous tissues and they influence some fatty acids con-
tent in mammary tumors.
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